Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy CPI-613 + Cytarabine + Mitoxantrone
Indication/Tumor Type acute myeloid leukemia
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown acute myeloid leukemia not applicable CPI-613 + Cytarabine + Mitoxantrone Phase I Actionable In Phase I trial, the combination therapy, CPI-613 with Cytosar-U and Novantrone (Mitoxantrone), resulted in an overall response rate of 50% (31/62) in acute myeloid leukemia patients and a median survival of 6.7 months, and in patients over 60 years of age, the combined therapy led to a 47% (15/32) complete response rate and median survival of 6.9 months (PMID: 29437791). 29437791
PubMed Id Reference Title Details
(29437791) A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Full reference...